Driving Compliance, Insight, and Innovation in Pharma

With evolving regulatory expectations and increasingly complex manufacturing environments, pharmaceutical companies are turning to advanced analytics platforms to not just keep up—but to lead. During the Pharmaceutical Industry Track at Conneqt 2025, leaders from across the life sciences came together to discuss how leveraging innovative technologies, like Seeq, can help them tackle one of the sector’s most persistent challenges: transforming massive volumes of regulated data into actionable, auditable insights. 

The theme of this year’s event, All In, resonated deeply across these pharma sessions. Attendees saw firsthand how going all in on analytics can empower teams to investigate faster, qualify smarter, and build stronger systems for compliance and innovation. 

Here are some of the standout moments from the Pharma Track. 

Eli Lilly: Simplifying deviation investigations and keeping assets in a qualified state

Eli Lilly shared two impactful stories that showcased Seeq’s versatility—from reactive investigations to proactive system oversight. 

First, the team demonstrated how they use investigative analytics and quality documentation workflows to streamline deviation handling. By leveraging Seeq to trace process anomalies, engineers were able to accelerate root cause analysis and enhance transparency in regulatory documentation. By leveraging PI Event Frames integrated with Seeq, the team streamlined this process.  

A notable use case involved verifying equipment cleanliness. Within just two hours (versus an estimated two days), the team isolated 40 relevant batches out of 3,000 using Event Frames—pinpointing potential early sampling issues with precision. Seeq’s compatibility to GMP standards allowed them to validate the analysis and avoid lengthy, costly experimental investigations. The result: a data-driven, defensible investigation, without resorting to worst-case assumptions.

Later, they introduced their forward-thinking assets qualification monitoring (AQM) by exception initiative. Ensuring assets remain in a “qualified state” is critical for producing quality medicines. But traditional processes were manual, inconsistent, and time-consuming—taking up to 10 hours per month per asset. 

Using Seeq Vantage and AI, Eli Lilly built a system that monitors qualified equipment across sites, flagging only exceptions rather than flooding teams with routine data and automatically generating routine reports for submission to the regulatory bodies. This shift empowers engineers to focus on real risks while maintaining a state of control—faster, smarter, and with fewer compliance headaches. 

Sanofi: From Event to Insight—Data-Driven Root Cause Analysis

Sanofi presented a compelling case study on loss of sterility during aseptic processing. Their team walked through a real-world event, where analytics played a central role in investigating, identifying root causes, and redesigning the test system. 

With Seeq, they could rapidly reconstruct the timeline, correlate diverse datasets, and simulate scenarios—turning a high-stakes deviation into an opportunity to strengthen their system. The impact went beyond operational improvements: it influenced regulatory decisions, demonstrating how advanced analytics can directly support GMP compliance and risk-based thinking.
 

Regeneron: Scaling up with Seeq in tech transfer and manage events fatigue

Tech transfer is always a challenge—but Regeneron is meeting it head-on with Seeq. Their team showcased how they use the platform to support process scale-up and commercialization. Seeq enabled rapid comparisons across pilot and production scales, flagged discrepancies early, and ensured consistency across batches. 

By embedding Seeq in their tech transfer workflows, Regeneron reduced the cycle time between development and commercial production, all while strengthening data traceability and confidence in results. 

And once the processes are running, Seeq helps the team monitor effectively. Specifically, on the alarm monitoring front, Seeq helped cut alarm fatigue dramatically—from 700 alerts per batch down to about 40 per month across three areas. By applying logic to suppress transient events and consolidate notifications, Regeneron delivered smarter alerts with actionable context via Teams, email, or SMS. 

Seeq: purpose-built for pharma analytics 

To cap it off, Seeq itself introduced the new Seeq for Pharma: Analytics & AI Suite—a solution specifically designed for GMP-regulated environments.  

The pharmaceutical industry faces unique challenges—stringent regulations, conservative data practices, and the constant need for validated, GMP-compliant solutions. To meet these needs, Seeq has launched the Seeq for Pharma: Analytics & AI Suite, a dedicated version of the platform designed specifically for pharmaceutical applications. 

This suite builds on years of collaboration with pharma customers, adding features like audit trails, locking and versioning of analyses, enhanced visualization tools, and structured change management to simplify (re)validation of software updates.  

The new software suite meets the rigorous needs of pharmaceutical operations while enabling cutting-edge analytics, helping pharma teams embed analytics into the fabric of quality, compliance, and continuous improvement. 

From Investigation to Innovation

Across all presentations, a common thread emerged: Seeq is enabling pharmaceutical manufacturers to turn isolated data into institutional insight. With the new capabilities introduced with the Seeq for Pharma Analytics & AI Suite, it is becoming easier than ever to embed advanced data analytics in GMP decision making and develop sophisticated solutions to govern key workflows as various stages of the drug lifecycle.  

By going All In on Seeq, pharma companies are not only enhancing decision making and compliance—they’re transforming them into a catalyst for innovation. 

To learn more about the impact of Seeq in pharma, visit our Video Hub.